FMR1 and fragile X syndrome: To test our hypothesis, we used a combination of human pluripotent stem cell (hPSC)—derived oligodendrocytes (FMR1 knockout and FXS individual‐derived) and Fmr1 knockout rats to assess the impact of FMRP loss on mammalian oligodendrocyte development.